Evidence map›Paper›PMID 39325839›Full record

ArticlePLoS pathogens2024

DNA methylation profiling identifies TBKBP1 as potent amplifier of cytotoxic activity in CMV-specific human CD8+ T cells.

Zheng Yu, Varun Sasidharan-Nair, Thalea Buchta, Agnes Bonifacius, Fawad Khan, Beate Pietzsch, Hosein Ahmadi, Michael Beckstette, Jana Niemz, Philipp Hilgendorf and 11 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zheng YuDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Varun Sasidharan-NairDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Thalea BuchtaInstitute of Genetics, Technische Universität Braunschweig, Braunschweig, Germany.
Agnes BonifaciusInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Fawad KhanDepartment Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Beate PietzschDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Hosein AhmadiDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Michael BeckstetteDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Jana NiemzDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Philipp HilgendorfMikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Philip MausbergInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Andreas KellerClinical Bioinformatics, Saarland University, Saarbrücken, Germany.
Christine FalkGerman Center for Infection Research (DZIF), Thematical Translation Unit-Immunocompromised Host (TTU-IICH), partner site Hannover-Braunschweig, Germany.
Dirk H BuschInstitute for Medical Microbiology, Immunology and Hygiene, Technical University Munich (TUM), Munich, Germany.
Kilian SchoberMikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Luka Cicin-SainGerman Center for Infection Research (DZIF), Thematical Translation Unit-Immunocompromised Host (TTU-IICH), partner site Hannover-Braunschweig, Germany.
Fabian MüllerIntegrative Cellular Biology and Bioinformatics, Saarland University, Saarbrücken, Germany.
Melanie M BrinkmannInstitute of Genetics, Technische Universität Braunschweig, Braunschweig, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Stefan FloessDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Jochen HuehnDepartment Experimental Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID 0000-0001-8071-1379

Funding

German Research Foundation 431451204Germany's Excellence Strategy 390874280
6 · The paper itself

Abstract

Epigenetic mechanisms stabilize gene expression patterns during CD8+ T cell differentiation. Although adoptive transfer of virus-specific T cells is clinically applied to reduce the risk of virus infection or reactivation in immunocompromised individuals, the DNA methylation pattern of virus-specific CD8+ T cells is largely unknown. Hence, we here performed whole-genome bisulfite sequencing of cytomegalovirus-specific human CD8+ T cells and found that they display a unique DNA methylation pattern consisting of 79 differentially methylated regions (DMRs) when compared to memory CD8+ T cells. Among the top demethylated DMRs in cytomegalovirus-specific CD8+ T cells was TBKBP1, coding for TBK-binding protein 1 that can interact with TANK-binding kinase 1 (TBK1) and mediate pro-inflammatory responses in innate immune cells downstream of intracellular virus sensing. Since TBKBP1 has not yet been reported in T cells, we aimed to unravel its role in virus-specific CD8+ T cells. TBKBP1 demethylation in terminal effector CD8+ T cells correlated with higher TBKBP1 expression at both mRNA and protein level, independent of alternative splicing of TBKBP1 transcripts. Notably, the distinct DNA methylation patterns in CD8+ T cell subsets was stable upon long-term in vitro culture. TBKBP1 overexpression resulted in enhanced TBK1 phosphorylation upon stimulation of CD8+ T cells and significantly improved their virus neutralization capacity. Collectively, our data demonstrate that TBKBP1 modulates virus-specific CD8+ T cell responses and could be exploited as therapeutic target to improve adoptive T cell therapies.

Indexed as

CD8-Positive T-LymphocytesCytomegalovirusDNA MethylationProtein Serine-Threonine KinasesCytomegalovirus InfectionsHumansProtein Serine-Threonine KinasesTBK1 protein, human

Identifiers

PMID39325839
PMCPMC11460711

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.